Mutant p53 protein expression and antioxidant status deficiency in breast cancer

Authors

  • Zorka Milicevic Laboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia
  • Jelena Kasapovic Laboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia
  • Ljubica Gavrilovic Laboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia
  • Zorka Milovanovic National Center of Cancer Research (NCRC), Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia
  • Vladan Bajic Department for Radiobiology and Molecular Genetics, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia
  • Biljana Spremo-Potparevic Department of Biology and Human Genetics, Institute of Physiology, Faculty of Pharmacy, Vojvode Stepe 450, University of Belgrade, 11 000 Belgrade, Serbia

Keywords:

antioxidants, breast carcinoma, lipid peroxidation, p53

Abstract

It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitopespecific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Δp53 (45 kDa) and isoform of ~ 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p<0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p<0.001; catalase, CAT, p<0.01; glutathione reductase, GR, p<0.001; glutathione, GSH, p<0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p<0.05 ) and lowered antioxidant activity of CAT (- 0.437, p<0.01) in the breast cancer patients.

Downloads

Published

2014-06-23

How to Cite

Milicevic, Z., Kasapovic, J., Gavrilovic, L., Milovanovic, Z., Bajic, V., & Spremo-Potparevic, B. (2014). Mutant p53 protein expression and antioxidant status deficiency in breast cancer. EXCLI Journal, 13, 691–708. Retrieved from https://www.excli.de/index.php/excli/article/view/732

Issue

Vol. 13 (2014)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).